Medix Biochemica acquires CANDOR Bioscience
The acquisition strengthens Medix Biochemica’s portfolio in critical raw materials for in vitro diagnostics (IVD)
Medix Biochemica, a global leader in the supply of critical raw materials for the in vitro diagnostics (IVD) industry, announced the acquisition of CANDOR Bioscience GmbH, a Germany-based developer and manufacturer of premium immunoassay solutions. The acquisition both strengthens Medix Biochemica’s range of high-quality raw materials to the worldwide IVD industry and enhances its capabilities to support test manufacturers in immunoassay development. Following the transaction, CANDOR Bioscience’s high-quality operations will remain in Wangen im Allgäu, Germany.
CANDOR Bioscience, founded in 2004 by Dr Tobias Polifke and Dr Peter Rauch, is a German provider of a comprehensive selection of premium solutions for immunoassays, including HAMA and interference blockers, surface blockers, stabilizers and buffer solutions. By using CANDOR Bioscience’s solutions, immunoassay manufacturers can improve reliability of test results, simplify assay designs and reduce process times.
“We are delighted to welcome CANDOR into the Medix Biochemica family. The partnership with CANDOR strengthens Medix Biochemica’s ability to support our customer base by adding complementary expertise in immunoassay development and broadening our offering of critical IVD raw materials with a leading portfolio of premium blockers and stabilizers. Together, we will continue to provide the highest quality raw materials that enable diagnostic innovation, and we look forward to a successful collaboration with the CANDOR team,” says Steve Ferguson, CEO of Medix Biochemica.
Dr Tobias Polifke and Dr Peter Rauch, co-founders and Managing Directors of CANDOR Bioscience, are excited about the partnership: “Joining forces with Medix Biochemica is an exciting milestone for CANDOR. We are proud of our legacy in providing differentiated, high-performance solutions for immunoassay development, and we share Medix Biochemica’s commitment to quality and innovation. By combining our capabilities and offerings, we will be better positioned to support the evolving needs of our customers. Medix Biochemica’s products, including antibodies and quality control materials, perfectly complement our solutions, enhancing the value we offer to partners in the IVD industry”.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Scientists identify how repair protein finds DNA damage
IUPAP Young Scientist Prize in Optics for Dr. Eleftherios Goulielmakis
Drug discovery potential of natural microbial genomes - Advanced genetic technique yields novel antibiotic from ocean bacteria
Molecular movie shows displaced electrons drive gold nanoparticle oscillations - Result defies established models of nanoparticle behaviour
Novel anti-PSMA imaging agent quickly identifies prostate cancer lesions
Wood on our Skin - Flexible, biocompatible nanocellulose sensors
London Travel in Miniature - The BNC creates the London Nanotube , the smallest map of the London Underground
InnovationsAward for Postnova at analytica 2008
Miltenyi Biotec acquires microscopy specialist
Epigenomics: Licensee ARUP Laboratories Launches Septin9 Colorectal Cancer Blood Test in the United States
